Has dose-dense chemotherapy met an ICONic end?

Emily M. Hinchcliff; Larissa A. Meyer; Shannon N. Westin

doi:10.1016/S1470-2045(20)30276-X

Has dose-dense chemotherapy met an ICONic end?

Emily M. Hinchcliff, Larissa A. Meyer, Shannon N. Westin

Obstetrics and Gynecology

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	869-870
Number of pages	2
Journal	The Lancet Oncology
Volume	21
Issue number	7
DOIs	https://doi.org/10.1016/S1470-2045(20)30276-X
State	Published - Jul 2020

Funding

EMH reports no competing interests. LAM reports research funding from AstraZeneca. SNW reports personal fees for consulting from AstraZeneca, Circulogene, Clovis Oncology, Merck, Novartis, Pfizer, Roche/Genentech, GSK/Tesaro, and Eisai and research funding to her institution from ArQule, AstraZeneca, Bayer, Clovis Oncology, Cotinga Pharmaceuticals, Novartis, Roche/Genentech, and GSK/Tesaro. EMH is supported by a National Institutes of Health (NIH) T32 grant (CA101642). LAM is supported by a NIH K07 grant (CA201013). SNW is supported by NIH SPORE in Ovarian Cancer (1P50CA217685-01) and a Gynecologic Oncology Group Foundation Scholar Investigator Award.

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1470-2045(20)30276-X

Cite this

@article{c5ac4a753c2b4f03bbf6551a82a8dccd,

title = "Has dose-dense chemotherapy met an ICONic end?",

author = "Hinchcliff, {Emily M.} and Meyer, {Larissa A.} and Westin, {Shannon N.}",

note = "Funding Information: EMH reports no competing interests. LAM reports research funding from AstraZeneca. SNW reports personal fees for consulting from AstraZeneca, Circulogene, Clovis Oncology, Merck, Novartis, Pfizer, Roche/Genentech, GSK/Tesaro, and Eisai and research funding to her institution from ArQule, AstraZeneca, Bayer, Clovis Oncology, Cotinga Pharmaceuticals, Novartis, Roche/Genentech, and GSK/Tesaro. EMH is supported by a National Institutes of Health (NIH) T32 grant (CA101642). LAM is supported by a NIH K07 grant (CA201013). SNW is supported by NIH SPORE in Ovarian Cancer (1P50CA217685-01) and a Gynecologic Oncology Group Foundation Scholar Investigator Award. Funding Information: EMH reports no competing interests. LAM reports research funding from AstraZeneca. SNW reports personal fees for consulting from AstraZeneca, Circulogene, Clovis Oncology, Merck, Novartis, Pfizer, Roche/Genentech, GSK/Tesaro, and Eisai and research funding to her institution from ArQule, AstraZeneca, Bayer, Clovis Oncology, Cotinga Pharmaceuticals, Novartis, Roche/Genentech, and GSK/Tesaro. EMH is supported by a National Institutes of Health (NIH) T32 grant ( CA101642 ). LAM is supported by a NIH K07 grant ( CA201013 ). SNW is supported by NIH SPORE in Ovarian Cancer ( 1P50CA217685-01 ) and a Gynecologic Oncology Group Foundation Scholar Investigator Award.",

year = "2020",

month = jul,

doi = "10.1016/S1470-2045(20)30276-X",

language = "English (US)",

volume = "21",

pages = "869--870",

journal = "The Lancet Oncology",

issn = "1470-2045",